Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-2,000
Closed -$480K 400
2021
Q4
$480K Sell
2,000
-4,500
-69% -$1.16M 0.06% 264
2021
Q3
$1.84M Buy
6,500
+3,000
+86% +$983K 0.24% 100
2021
Q2
$1.21M Buy
+3,500
New +$1.06M 0.16% 154

Other funds holding BIIB

Avestar Capital's BIIB Position: Q1 2026 in Review

Avestar Capital increased its Biogen (BIIB) stake by 2% in Q1 2026, buying an estimated $12.7K and bringing the position to 3,604 shares worth $661K. The position accounts for 0.04% of the portfolio, ranked #294.

Avestar Capital first reported a position in BIIB in Q4 2017 and has held it in 34 quarters since. The position peaked at $852K in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Avestar Capital held 3,604 shares of Biogen worth $661K as of Q1 2026.
  • Avestar Capital bought 69 Biogen shares in Q1 2026, an estimated $12.7K.
  • Biogen made up 0.04% of Avestar Capital's portfolio in Q1 2026, its #294 holding.
  • Avestar Capital first reported a position in Biogen in Q4 2017 and has held it in 34 quarters since.
  • Avestar Capital's Biogen position peaked at $852K in Q3 2018.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.